Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,441 stopped studies mapped to Leukemia and descendants · 87% state a reason
Over the 1,441 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01643603 | Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic… | Phase 1 | terminated | Jul 18, 2012 | Barbara Ann Karmanos Cancer Institute | Study terminated due to slow accrual. | Enrollment / accrual |
| NCT03739606 | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer | Phase 2 | withdrawn | Nov 14, 2018 | City of Hope Medical Center | RSS recommendation | Other (stated, no rule matched) |
| NCT03709576 | Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell… | Phase 2 | terminated | Oct 17, 2018 | Milton S. Hershey Medical Center | Funding pulled | Funding |
| NCT01300611 | TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation(USBTXA127CBT) | Phase 1 | terminated | Feb 21, 2011 | Tarix Pharmaceuticals | not stated | Not stated |
| NCT02538614 | Study of Idelalisib in Combination With BI 836826 in Participants With Chronic… | Phase 1 | terminated | Sep 2, 2015 | Gilead Sciences | not stated | Not stated |
| NCT01799889 | Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib… | Phase 2 | terminated | Feb 27, 2013 | Gilead Sciences | Sponsor's decision to discontinue development of entospletinib. | Sponsor / business decision |
| NCT02782403 | Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase… | Phase 1 | terminated | May 25, 2016 | M.D. Anderson Cancer Center | Terminated per PI's request at the time of CR. Study was closed due to low/slow accrual due to… | Enrollment / accrual |
| NCT04493099 | Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or… | Phase 1 / Phase 2 | withdrawn | Jul 30, 2020 | M.D. Anderson Cancer Center | The original sponsor was acquired by a new company and has elected to end funding for all… | Investigator |
| NCT04094766 | Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R… | Phase 1 | withdrawn | Sep 19, 2019 | Second Affiliated Hospital of Xi'an Jiaotong University | Production plan adjustment | Other (stated, no rule matched) |
| NCT01656252 | Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission(PrE0901) | Phase 1 / Phase 2 | terminated | Aug 2, 2012 | PrECOG, LLC. | Study stopped per Novartis request due to futility from another study. | Efficacy / futility |
| NCT01483690 | A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL | Phase 1 / Phase 2 | terminated | Dec 1, 2011 | Therapeutic Advances in Childhood Leukemia Consortium | Toxicity | Safety / toxicity |
| NCT01498445 | An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and… | Phase 1 / Phase 2 | terminated | Dec 23, 2011 | M.D. Anderson Cancer Center | The study was terminated early during the phase II portion of the study due to slow enrollment. | Enrollment / accrual |
| NCT02953561 | Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid… | Phase 1 / Phase 2 | terminated | Nov 2, 2016 | M.D. Anderson Cancer Center | PDOL request | Other (stated, no rule matched) |
| NCT02750254 | Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation | Phase 1 | terminated | Apr 25, 2016 | Washington University School of Medicine | Toxicity. Only enrolled patients in phase I portion of trial. | Safety / toxicity |
| NCT00551239 | Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed… | Phase 3 | withdrawn | Oct 30, 2007 | CTI BioPharma | not stated | Not stated |
| NCT02012231 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in… | Phase 1 | terminated | Dec 16, 2013 | Fore Biotherapeutics | not stated | Not stated |
| NCT03037645 | Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers | Phase 1 / Phase 2 | terminated | Jan 31, 2017 | Sunesis Pharmaceuticals | Phase 1b portion completed. Sponsor decided not to proceed with P2 portion of study. Vecabrutinib… | Sponsor / business decision |
| NCT03963024 | Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT(TrRaMM-TMI) | Phase 1 | terminated | May 24, 2019 | IRCCS San Raffaele | low rate of enrolment | Enrollment / accrual |
| NCT04128020 | Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation… | Phase 1 | withdrawn | Oct 16, 2019 | Sherif Farag | Funder withdrew funding after not accruing any subjects after 1 year. | Enrollment / accrual |
| NCT00020969 | Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes | Phase 2 | terminated | Jan 27, 2003 | CTI BioPharma | not stated | Not stated |
| NCT02786485 | Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After… | Phase 1 | withdrawn | Jun 1, 2016 | Bellicum Pharmaceuticals | not stated | Not stated |
| NCT00981799 | Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL | Phase 1 / Phase 2 | terminated | Sep 22, 2009 | Therapeutic Advances in Childhood Leukemia Consortium | Slow accrual rate | Enrollment / accrual |
| NCT02991898 | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies | Phase 2 | terminated | Dec 14, 2016 | Masonic Cancer Center, University of Minnesota | Considering new technology for product. | Other (stated, no rule matched) |
| NCT03888534 | Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute… | Phase 1 | withdrawn | Mar 25, 2019 | Millennium Pharmaceuticals, Inc. | Business decision (no safety or efficacy concerns) | Safety / toxicity |
| NCT00506948 | Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute… | Phase 2 | terminated | Jul 25, 2007 | M.D. Anderson Cancer Center | Halted due to high incidence of veno-oclusive disease of the liver. | Other (stated, no rule matched) |
| NCT00726830 | Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer | N/A | terminated | Aug 1, 2008 | M.D. Anderson Cancer Center | Low Accrual. | Enrollment / accrual |
| NCT01658007 | Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute…(SIR-MO-1101) | Early Phase 1 | terminated | Aug 6, 2012 | Children's Hospital Medical Center, Cincinnati | Slow Accrual | Enrollment / accrual |
| NCT03985215 | The Value of Follow-Up After Childhood Acute Lymphoblastic Leukaemia in Denmark - Family… | — | withdrawn | Jun 13, 2019 | University of Aarhus | Overlapping with another danish questionnaire study | Other (stated, no rule matched) |
| NCT03515200 | Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic… | Phase 1 | terminated | May 3, 2018 | St. Jude Children's Research Hospital | Due to departure of PI from St. Jude | Other (stated, no rule matched) |
| NCT00914940 | Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts… | Phase 2 | terminated | Jun 5, 2009 | Fred Hutchinson Cancer Center | Did not reach one of the primary endpoints of decreased total acute GVHD | Other (stated, no rule matched) |
| NCT02767934 | Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic… | Phase 2 | terminated | May 11, 2016 | University of Washington | Terminated due to lack of efficacy | Efficacy / futility |
| NCT00674427 | Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After… | Phase 1 | terminated | May 7, 2008 | University of Pennsylvania | Insufficient funds | Funding |
| NCT03807063 | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood… | Phase 1 | withdrawn | Jan 16, 2019 | Fred Hutchinson Cancer Center | Insufficient funding | Funding |
| NCT00983528 | Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | terminated | Sep 24, 2009 | University of California, San Diego | Support withdrawn due to slow accrual | Enrollment / accrual |
| NCT02730884 | Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With… | Phase 2 | terminated | Apr 7, 2016 | M.D. Anderson Cancer Center | Terminated Per PIs request due to low accrual | Enrollment / accrual |
| NCT00004114 | Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced… | Phase 1 | withdrawn | Feb 16, 2004 | Jonsson Comprehensive Cancer Center | Study never opened | Other (stated, no rule matched) |
| NCT00004878 | Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid… | Phase 2 | withdrawn | Apr 28, 2004 | Jonsson Comprehensive Cancer Center | study never opened | Other (stated, no rule matched) |
| NCT00234000 | Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes | Phase 1 | terminated | Oct 6, 2005 | Jonsson Comprehensive Cancer Center | The study was closed due to poor enrollment | Enrollment / accrual |
| NCT03059615 | A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects… | Phase 2 | withdrawn | Feb 23, 2017 | Immune System Key Ltd | No recruitment since initiation | Enrollment / accrual |
| NCT02781467 | A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell… | Phase 1 | terminated | May 24, 2016 | Celularity Incorporated | Business Decision | Sponsor / business decision |
| NCT04106076 | Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia | Phase 1 | withdrawn | Sep 26, 2019 | Cellectis S.A. | The trial was discontinued due to sponsor's decision and not a consequence of any safety concern | Safety / toxicity |
| NCT01551043 | Allo CART-19 Protocol | Phase 1 | terminated | Mar 12, 2012 | University of Pennsylvania | Administrative Reasons | Other (stated, no rule matched) |
| NCT03152526 | CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK)… | N/A | terminated | May 15, 2017 | Miltenyi Biotec B.V. & Co. KG | Slow enrollment | Enrollment / accrual |
| NCT03628053 | Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory…(OBERON) | Phase 3 | withdrawn | Aug 14, 2018 | Novartis Pharmaceuticals | Novartis is no longer pursuing this study because of planned investigation of novel CAR-T therapies… | Other (stated, no rule matched) |
| NCT03265717 | DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1… | Phase 2 | terminated | Aug 29, 2017 | Invectys | sponsor decision | Sponsor / business decision |
| NCT04013880 | ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic… | Phase 1 / Phase 2 | withdrawn | Jul 10, 2019 | Vanderbilt-Ingram Cancer Center | Loss of funding | Funding |
| NCT01003769 | Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic… | Phase 1 / Phase 2 | terminated | Oct 29, 2009 | Mayo Clinic | Lack of funding | Funding |
| NCT01796470 | Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory… | Phase 2 | terminated | Feb 21, 2013 | Gilead Sciences | Study was terminated due to safety measures. | Safety / toxicity |
| NCT03718143 | AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis | Phase 2 | terminated | Oct 24, 2018 | NYU Langone Health | Safety concerns | Safety / toxicity |
| NCT01615042 | Phase I Study of Lenalidomide in Patients With Acute Leukemia | Phase 1 | terminated | Jun 8, 2012 | Mehrdad Abedi, MD | Lack of enrollment | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Dec 17, 2020source: clinicaltrials